25
Participants
Start Date
November 15, 2024
Primary Completion Date
February 28, 2027
Study Completion Date
June 30, 2027
Rifapentine
Children 2-11 years received standard HIV treatment and 3HP (RPT/INH weekly for 12 weeks) for TB prevention. Children \<2 years receive standard HIV treatment, a single-dose of extrapolated weekly RPT/INH, followed by standard INH prophylaxis. Safety and pharmacokinetics will be evaluated.
Dolutegravir
All children in this study are living with HIV and thus dolutegravir is a standard part of treatment; in this study we will collect blood samples to measure dolutegravir levels during combination treatment with rifapentine/isoniazid treatment for TB prevention
RECRUITING
University College Hospital, Ibadan
APIN Public Health Initiatives
UNKNOWN
University of Cape Town
OTHER
Brigham and Women's Hospital
OTHER